Supporting Information

Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethane as P₂-Ligands: Synthesis, Biological Evaluation, and Protein-Ligand X-Ray Crystal Structure.

Arun K. Ghosh, Bruno D. Chapsal, Garth L .Parham, Melinda Steffey, Jonhson Agniswamy, Yuan-Fang Wang, Irene T. Weber, Masayuki Amano, and Hiroaki Mitsuya.

Table of Contents:

Table 1. HPLC Purity of Inhibitors 21-31	S2
Table 2. High and Low Resolution Mass Spectrometry Data for Inhibitors 21 to 31	S3
Table 3. Crystallographic Data Collection and Refinement Statistics	S4

HPLC Analytical Purity

	Method A		Meth	nod B	
Inhibitor	R _t (min)	Purity (area %)	R _t (min)	Purity (area %)	
21	12.87	95.1	15.3	95.8	
22	11.54	99.1	15.03	99.3	
23	9.17	95.1	12.25	95.2	
24	8.82	97.2	12.96	96.4	
25	13.64	97.9	16.31	97.9	
26	10.45	99.9	14.54	99.9	
27	8.25	98.1	11.75	98.3	
28	12.92	96.8	15.97	99.9	
29	14.80	95.2	17.30	95.0	
30	15.04	97.7	17.55	95.7	
31	8.97	97.0	12.8	99.2	

Table 1. Analytical Purity of Inhibitors **21** to **31** determined by HPLC.

HPLC conditions:

Method A = Agilent Eclipse XDB-C18 (4.6 x 150 mm, 5 μ m); t = 0-1 min (MeCN:H₂O:TFA 20:80:0.05), t = 1-20 min (*gradient to* MeCN:H₂O:TFA 90:10:0.05), t = 20-25 min (MeCN:H₂O:TFA 90:10:0.05); Flow = 1.5 mL/min; single detection wavelength λ = 215 nm, T = 25 °C, injection volume 30 μ L, 10 min equilibration time between run.

Method B = Agilent Eclipse XDB-C18 (4.6 x 150 mm, 5 μ m); t = 0-1 min (MeOH:H₂O:TFA 25:75:0.05), t = 1-20 min (*gradient to* MeOH:H₂O:TFA 95:5:0.05), t = 20-25 min (MeOH:H₂O:TFA 95:5:0.05); Flow = 1.5 mL/min; single detection wavelength λ = 215 nm, T = 25 °C, injection volume 30 μ L, 10 min equilibration time between run.

Mass Spectrometry Data

Inhibitor	Molecular Formula	HRMS Technique	Ion	Calculated	Found
21	$C_{29}H_{38}N_2O_8S$	ESI	[M+Na] ⁺	597.2247	597.2251
22	$C_{29}H_{40}N_2O_8S$	LRMS-ESI	[M+Na] ⁺	599.2	599.3
23	$C_{28}H_{39}N_3O_7S$	ESI	[M+Na] ⁺	584.2406	584.2410
24	$C_{29}H_{40}N_2O_8S$	ESI	[M+Na] ⁺	599.2403	599.2401
25	$C_{30}H_{42}N_2O_8S$	ESI	$[M+H]^+$	591.2740	591.2742
26	$C_{29}H_{40}N_2O_8S$	ESI	[M+H] ⁺	577.2584	577.2572
27	$C_{28}H_{39}N_3O_7S$	ESI	[M+Na] ⁺	584.2406	584.2398
28	$C_{30}H_{42}N_2O_8S$	ESI	[M+Na] ⁺	613.2560	613.2555
29	$C_{28}H_{39}N_3O_7S$	LRMS- ESI	$[M+H]^+$	575.3	575.1
30	$C_{29}H_{40}N_2O_8S$	LRMS- ESI	[M+H] ⁺	575.3	575.1
31	$C_{31}H_{45}N_3O_7S$	LRMS-ESI	$[M+H]^+$	604.8	604.3

 Table 2. High and Low Resolution Mass Spectrometry Data for Inhibitors 21 to 31.

Crystallographic Data Collection and Refinement Statistics

Table 3. Crystallographic Data C	Collection and Refinement Statistics
----------------------------------	--------------------------------------

	PR-GRL-0489A
Space group	P2 ₁ 2 ₁ 2
Unit cell dimensions: (Å)	
Α	58.39
В	86.55
С	45.85
Resolution range (Å)	50-1.45
Unique reflections	41,487
R _{merge} (%) overall (final shell)	7.2 (41.8)
$I/\sigma(I)$ overall (final shell)	16.0 (2.0)
Completeness (%) overall (final shell)	98.4 (88.5)
Data range for refinement (Å)	10-1.45
R (%)	16.0
R _{free} (%)	21.9
No. of solvent atoms	142
RMS deviation from ideality	
Bonds (Å)	0.010
Angle distance (Å)	0.029
Average B-factors (Å ²)	
Main-chain atoms	17.4
Side-chain atoms	23.6
Inhibitor	14.1
Solvent	26.2